Introduction
============

Molecular imaging is a fast growing research area involving the development and evaluation of novel tools, reagents and methods to image specific molecular pathways *in vivo*; particularly those that are key targets in disease processes [@B1]-[@B3]. Within this area of research, positron emission tomography (PET) has emerged as one of the most powerful clinical imaging techniques because it can provide critical *in vivo* information on the distribution of radiolabeled biomolecules for non-invasive diagnosis [@B4]. Fluorescence imaging is another valuable technique that has been used for intraoperative tumor detection [@B1]. Since both PET and fluorescence imaging have unique features suitable for clinical application, a system that integrates these two imaging modalities could greatly benefit patient management, for example by providing complimentary diagnosis information during surgery in a non-invasive manner. Stimulated by the potential that such dual modality imaging agent may present in the clinical field [@B5], [@B6], we have recently investigated the radiofluorination of BODIPY dyes. Inspired by the work of Perrin [@B7]-[@B13], Blower [@B14]-[@B16], and Tsien [@B17], we used the boron center as a site for radiofluorination [@B18], [@B19] and prepared the first example of a \[^18^F\]BODIPY as a dual modality imaging agent [@B20]. This new approach, which has been recently adopted by Weissleder and Mazitschek [@B21], [@B22], is attractive because the positron emitting and fluorescence properties of the imaging agent are confined to the same molecular compartment. It is also based on the use of ^18^F, a radionuclide of choice for PET [@B23]-[@B30].

The successful implementation of this approach is non-trivial because of the stability of the B-F bond in the parent BODIPY dye. After an initial series of studies on the activation of the B-F bond with Lewis acidic reagents [@B31] such as trimethylsilyl triflate (TMSOTf) [@B19], we found that introduction of ^18^F could be achieved from the corresponding hydroxide derivative in aqueous media at low pH or in MeCN with TMSOTf as a B-OH bond activator (no-carrier added method, Scheme 1/Figure [A](#FA){ref-type="fig"}) [@B20], Weissleder and Mazitschek showed that radiofluorination could be carried out in MeCN by converting the BODIPY dye into a boron-triflate derivative and by allowing it to react with ^18^Fˉ (Figure [A](#FA){ref-type="fig"}) [@B21], [@B22]. These two approaches rest on the intermediacy of an activated BODIPY dye with a labile hydroxide or a triflate anion bound to the boron atom. Despite the undisputed success of both approaches, some problems remain. The first approach requires the synthesis of a BODIPY hydroxide as well as acidic conditions that may lead to decomposition reactions. The second approach necessitates the synthesis of a boron triflate derivative.

As part of our continuing interest in this field of research, we have decided to broaden the scope of our studies and test Lewis acidic reagents that would promote fluoride exchange reactions, thus circumventing the need for an activated hydroxide or triflate derivative. In this report, we describe the results of this effort and introduce a simple and highly efficient approach toward integrated PET/fluorescence imaging agents, based on BODIPY dyes. We also demonstrate the potential of our approach for tumor imaging.

Materials and Methods
=====================

1,3,5,7-tetramethyl-8-\[4-(N,N-dimethylamino)phenyl\]-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene were prepared according to the reported procedures [@B32]. Solvents were dried by passing through an alumina column (toluene and CH~2~Cl~2~) or refluxing under N~2~ over Na/K (Et~2~O and THF). All other solvents and chemicals were used as received. Ambient temperature NMR spectra were recorded on a Varian Unity Inova 400 FT NMR (399.59 MHz for ^1^H, 128.20 MHz for ^11^B, 100.45 MHz for ^13^C, and 375.89 MHz for ^19^F) spectrometer. Chemical shifts (δ) are given in ppm and are referenced against residual solvent signals (^1^H, ^13^C) or external BF~3~-Et~2~O (^11^B, ^19^F). Elemental analyses were performed at Atlantic Microlab (Norcross, GA). Electrospray mass spectra were obtained with a SciexQstarr Pulsar and a Protana Nanospray ion source. The radiosynthetic work was carried out with the following equipment and methods. The syringe filter and polyethersulfone membranes (pore size, 0.22 μm; diameter, 13 mm) were obtained from Nalge Nunc International (Rochester, NY). Analytical reversed-phase high-performance liquid chromatography (HPLC) was on a Waters 515 chromatography system with a Waters 2487 dual λ absorbance detector and model 2200 scaler-ratemeter radiation detector from Ludlum Measurements, Inc. (Sweetwater, TX). Empower 2 software from Waters Corporation (Milford, MA) was used to record the chromatograms. HPLC was performed on a phenomenex Luna 5µ C18 column (250 × 4.6 mm). The flow was 1 mL/min, with the mobile phase starting from 95% solvent A (0.1% TFA in water) and 5% solvent B (0.1% TFA in MeCN) (0-2 min) to 5% solvent A and 95% solvent B at 22 min.

Synthesis of 1^+^OTf^-^
-----------------------

To a CH~2~Cl~2~ (5 mL) solution of 1,3,5,7-tetramethyl-8-\[4-(N,N-dimethylamino)phenyl\]-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (150 mg, 0.408 mmol) was added neat methyl trifluoromethanesulfonate (80 mg, 0.490 mmol) dropwise at ambient temperature. The formation of an orange precipitate was observed after stirring for 15 min. This solid was collected by filtration and washed with *n*-pentane (20 mL) and Et~2~O (5 mL) to afford a pure sample of **1**^+^OTf^-^ (147 mg, 68%). ^1^H NMR (399.59 MHz, DMSO-*d~6~*): δ 1.33 (s, 6H, dipyrrin-C*H*~3~), 2.45 (s, 6H, dipyrrin-C*H*~3~), 3.65 (s, 9H, N-C*H*~3~), 6.21 (s, 2H, dipyrrin-C*H*), 7.71 (d, 2H, ^3^*J*~H-H~ = 8.9 Hz, phenyl-C*H*), 8.13 (d, 2H, ^3^*J*~H-H~ = 8.9 Hz, phenyl-C*H*). ^13^C NMR (100.45 MHz, DMSO-*d~6~*): δ 14.6, 56.9, 121.9, 122.1, 130.3, 30.8, 136.2, 140.1, 143.0, 148.4, 155.9. ^19^F NMR (375.89 MHz, DMSO-*d~6~*): δ -77.1 (s, 3F, OTf), -142.9 (q, 2F, ^1^*J*~B-F~ = 32.2 Hz, BF~2~). ^11^B NMR (128.20 MHz, DMSO-*d~6~*): δ 0.89 (t, ^1^*J*~B-F~ = 32.9 Hz). HRMS (ESI^+^) calcd for **1**^+^ (C~22~H~27~BF~2~N~3~^+^): 382.2265, found: 382.2247.

Synthesis of 2-RGD
------------------

Compound **2** (BODIPY® R6G) (1.5 µmol) in 50 µL DMSO and *c*(RGDyK) (400 µg, 0.66 µmol, denoted as RGD) were mixed together and treated with *N*,*N*-diisopropylethylamine (5 µL). After 2 h incubation, the reaction mixture was subjected to HPLC purification. **2**-RGD (Rt = 11.9 min) was obtained in 80% yield. ESI-MS for **2**-RGD: m/z 942.4 for \[M+H\]^+^ (Chemical formula: C~45~H~55~BF~2~N~11~O~9~, calculated m/z value: 942.4).

Radiolabeling
-------------

Fluorine-18 was produced as \[^18^F\]fluoride ion by the ^18^O(p,n)^18^F reaction in \[^18^O\]water using a CTI/Siemens RDS112 11MeV cyclotron. \[^18^F\]fluoride was trapped by a QMA cartridge and eluted off with tetrabutylammonium bicarbonate (TBAB) into a 5-mL V-vial (Type I Borosilicate), followed by azeotropic drying. \[^18^F\]-fluoride was then dissolved in anhydrous MeCN for the labeling reactions.

Radiofluorination of **1**^+^: In a typical experimental, **1**^+^OTf^-^ (0.37 µmol) was mixed with SnCl~4~ (3.0 µmol) in MeCN (20 µL). The resulting solution was then combined with a MeCN solution (50 µL) of \[^18^F\]fluoride (10 ± 3 mCi). After shaking at room temperature for 10 min, an aliquot of the reaction mixture (50-100 µCi) was collected for HPLC analysis. Integration of the radio-chromatogram indicated a conversion with a RCY \> 95%. For animal studies, 3 ± 1 mCi of \[^18^F\]**1^+^** was purified by HPLC. The HPLC mobile phase was then removed by rotary evaporation and the activity was reconstituted in 1 mL phosphate-buffered saline (PBS) and passed through a 0.22 µm syringe filter for *in vivo* animal experiments. Counted from the end of bombardment, the drying step was 25 min. Other steps include the reaction time (10 min), the sample preparation time (approx. 5 min), HPLC purification (20 min), and the rotary evaporation of the solvent (10-15 min).

Radiofluorination of **2**: Compound **2** (130 µg, 0.23 µmol) was mixed with SnCl~4~ (3.0 µmol) in MeCN (20 µL). The resulting solution was then combined with a MeCN solution (50 µL) of \[^18^F\]fluoride (10 ± 3 mCi). After shaking at room temperature for 10 min, a portion of the reaction mixture (3 ± 1 mCi) was loaded on the HPLC for purification. \[^18^F\]**2**was obtained in a 79% labeling yield with an estimated specific activity of 35 ± 10 mCi/µmol.

Synthesis of \[^18^F\]**2**-RGD: \[^18^F\]**2**was azeotropically dried twice at 80 °C using anhydrous MeCN. Then RGD (200 µg, 0.33 µmol) in DMSO (100 µL) was added to \[^18^F\]**2** (2 mCi, 0.07 µmol), followed by addition of 2 µL diisopropylethylamine. The reaction remained at 50 °C under shaking for 15 min. After quenching the reaction with a 5% acetic acid solution (1 mL), a portion of the reaction mixture (1 ± 0.2 mCi) was loaded on the HPLC for purification. The HPLC solvents were removed by rotary evaporation and the activity was reconstituted in 1 mL PBS and passed through a 0.22 µm syringe filter for *in vivo* animal experiments. \[^18^F\]**2**-RGD was obtained in an 82% yield with an estimated specific activity of 19 ± 4 mCi/µmol.

MicroPET Imaging
----------------

Animal procedures were performed according to a protocol approved by the University of Southern California Institutional Animal Care and Use Committee. The detailed procedure was published previously [@B33]. In brief, each mouse was injected with 50 ± 10 μCi of the \[^18^F\] probe via the tail vein. The imaging data were achieved with the mice under anesthesia using isoflurane (5% for induction and 2% for maintenance in 100% O~2~). The regions of interest (ROIs) were converted to counts per gram per min based on the assumption of 1 g/mL tissue density. Dividing counts per gram per minute by injected dose gave the image ROI derived %ID/g values.

*Ex vivo*fluorescence imaging
-----------------------------

*Ex vivo*fluorescence imaging was performed using the Xenogen Lumina XR Imaging System and analyzed using the IVIS Living Imaging 3.0 software (Caliper Life Sciences, Alameda, CA, USA). The detailed information was reported previously in our publication [@B34].

Results and Discussion
======================

In our initial effort, we decided to investigate the radiofluorination of **1**^+^, a BODIPY dye decorated by a peripheral trimethylammonium group and isolated as a triflate salt. The fluoride exchange reaction was initially studied in aqueous media under acidic condition at pH 2.0 (Table [1](#T1){ref-type="table"}, entry 1), a set of conditions that has proven effective for the radiolabeling of fluoroborate species [@B15], [@B16], [@B35]. Unfortunately, this reaction only afforded a trace amount of \[^18^F\]**1**^+^ (\< 2% yield), with most of the BODIPY dye succumbing to the acidic conditions. This result led us to investigate the radiofluorination of **1**^+^ in acetonitrile (MeCN), using TMSOTf as an activator (entry 2). Under optimized conditions, this reaction afforded \[^18^F\]**1**^+^ with a yield approaching 20%. Increasing the amount of activator did not improve the yield because of the competitive formation of \[^18^F\]TMSF [@B20].

Faced with these limitations, we decided to investigate the use of alternative Lewis acid activators. Realizing that strong Lewis acids may hamper ^18^F**-**^19^F isotopic exchange by irreversible fluoride anion binding, we decided to focus on Lewis acids of intermediate strength. Using the anion accepting scale established by Gutmann in his seminal studies [@B36], we chose to start with a relatively weak Lewis acid such as ZnCl~2~. The results obtained with this Lewis acid provided an initial validation of our approach, with a non-negligible radiochemical yield (RCY) observed when the reaction was carried out in MeCN with an excess of ZnCl~2~ at elevated temperature (Table [1](#T1){ref-type="table"}, entries 3-6). However, these high temperature reactions were complicated by decomposition of the dye and formation of hydrophobic byproducts. Next, we decided to focus on the more Lewis acidic SnCl~4~. This Lewis acid proved remarkably efficient at promoting ^18^F-^19^F isotopic exchange, even at room temperature (entries 7-12). As illustrated by the crude HPLC traces shown in Figure [1](#F1){ref-type="fig"}, an almost quantitative yield was obtained when an 8-fold or 14-fold molar excess of SnCl~4~ was employed with respect to the starting BODIPY dye **1**^+^ (entries 8 and 9). We observed a decrease in yield at very high molar excess (80-fold excess, entry 10), a phenomenon most likely resulting from the sequestration of fluoride by the large excess of the tin reagent. The yield was not compromised with lower loading of **1**^+^ (entry 11). This approach can also be implemented with higher amounts of starting activity (50 *vs*. 10 mCi), affording the \[^18^F\]**1**^+^ with a specific activity close to 1 Ci/µmol (calculated based on starting activity and RCY, entry 12). We also noticed that more polar solvents such as DMSO compromised the yield, a phenomenon that we assign to increasing solvent-Lewis acid interactions (entry 3 and 7). The isotopic exchange reaction is also efficiently promoted by TiCl~4~ (entry 13) but not AlCl~3~ and AlF~3~ (entries 14-16) which presumably sequester \[^18^F\]fluoride rather than promoting exchange [@B37], [@B38].

We then studied the stability of \[^18^F\]**1^+^**in a PBS buffer at pH 7.5 over a period of several hours. The HPLC profile showed that 97% of \[^18^F\]**1^+^**remained after a 6 h incubation, thus indicating this derivative\'s remarkable resistance to hydrolysis at physiological pH (supporting information). In order to further validate our compound and demonstrate its potential for *in vivo* PET imaging, \[^18^F\]**1^+^** was injected into normal nude mice that were imaged using a microPET scanner at 0.5 h, 1 h, and 3 h post injection (supporting information). As expected, we did not observe obvious bone uptake even at 3 h post injection, which is consistent with the reported high stability of BODIPY dyes [@B20]. Next, we endeavoured to confirm the dual modality potential of the probe. The animal was euthanized and the liver, the kidneys, and a muscle sample were harvested for *ex vivo* PET/fluorescence imaging. As shown in Figure [2](#F2){ref-type="fig"}, the *ex vivo* microPET and fluorescence imaging correlate well with each other. We also sectioned a kidney of the animal and observed the natural green fluorescence of \[^18^F\]**1^+^** using a fluorescence microscope (Figure [2](#F2){ref-type="fig"}C). By comparison, only weak tissue auto-fluorescence was observed in the kidney of the control mouse (a mouse without \[^18^F\]**1**^+^ injection) (Figure [2](#F2){ref-type="fig"}D). These fluorescence images confirm the dual modality properties of the probe and also suggest that fluorescence microscopy can be used to study the localization of the radioactive probes within the tissue (for example, the distribution of a PET probe within the tumor tissue).

The clinical relevance of our approach to cancer imaging was established using human glioblastoma (U87MG) tumor-bearing mice as an animal model [@B39], [@B40]. Since it has been firmly established that the Arg-Gly-Asp (RGD) peptide binds to integrin α~v~β~3~ [@B41]-[@B44], a receptor protein that is over-expressed in U87MG cells, we considered the construction of a radiolabeled BODIPY/RGD peptide conjugate. In our proof of principle study, we found that the conditions used for the radiolableling of **1**^+^ could also be applied to **2**, a commercially available BODIPY *N*-succinimide ester (BODIPY® R6G), which was converted into \[^18^F\]**2** with a yield of 79% (Figure [3](#F3){ref-type="fig"}). Further, we found that the resulting radiolabeled dye \[^18^F\]**2** could be easily conjugated with the Arg-Gly-Asp (RGD) peptide [@B39] in MeCN and in the presence of DIPEA to afford \[^18^F\]**2-**RGD in 82% RCY. *In vivo* evaluation of \[^18^F\]**2-**RGD using U87MG tumor-bearing nude mice showed a strong PET signal from the liver and kidneys of the animal, in accordance with the lipophilic nature of the conjugate and its clearance via the urinary tract, respectively. More importantly, *in vivo* PET imaging showed a discernible tumor uptake of the conjugate. The dual modality imaging properties of the probe was confirmed by *ex vivo* fluorescence and microPET imaging experiments (Figure [3](#F3){ref-type="fig"}). The harvested liver, kidneys, and tumor showed a strong PET signal thus corroborating the *in vivo* imaging results. In a somewhat fortuitous fashion, we observed a much stronger fluorescence signal from the tumor than from the kidneys and liver. We rationalized this differences by the high vascularization of the kidneys and liver whose hemoglobin absorbs much of the excitation light (λ = 535 nm). The emission band of the BODIPY at λ~max~ 550 nm also coincides with the strong absorption bands of hemoglobin, leading to a further reduction of the fluorescence signal. These interferences are greatly diminished in the less vascularized tumor, which gives rise to a much stronger fluorescence signal. These images, and in particular those of the tumor, provide an original demonstration of the dual modality properties of this novel BODIPY-based cancer imaging probe (\[^18^F\]**2-**RGD). Such results bear no precedent, since previously reported cancer specific \[^18^F\]BODIPY conjugates are yet to be studied *in vivo* and imaged *in* or *ex vivo* [@B21], [@B22].

Conclusions
===========

We have discovered that Lewis acids such as SnCl~4~ can be used to promote the ^18^F-labeling of BODIPY dyes with high efficiency. We also provide evidence that our new approach can be applied to the preparation of PET/fluorescence BODIPY-based cancer imaging probes. We are currently testing the generality of our approach with a particular focus to extend it to BODIPY fluorophores and disease-specific conjugates that emit in the NIR region.

Supplementary Material
======================

###### 

Characterization of the BODIPY compounds and conjugates, their radiofluorination and their use for animal imaging.

###### 

Click here for additional data file.
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![Illustration of conditions recently used for the ^18^F-labeling of BODIPY dyes [@B20]-[@B22].](thnov03p0181g01){#FA}

![**Left:**UV trace of **1**^+^ as the standard reference. **Right:***Crude* radio-HPLC profile for the ^18^F-labeling of **1**^+^ from entry 8 in Table [1](#T1){ref-type="table"}.](thnov03p0181g03){#F1}

![Representative *ex vivo* microPET (A) and fluorescence (B) imaging of dissected organs of a nude mouse. The observation of \[^18^F\]**1**^+^ in mouse kidneys (C) and the kidney of a control animal (D). The animal was sacrificed after the microPET scan 3 h post injection. 1. Muscle. 2. Liver. 3. Kidneys. 4. Spleen.](thnov03p0181g04){#F2}

###### 

**Top**: Scheme for the synthesis of \[^18^F\]**2** and \[^18^F\]**2**-RGD and HPLC trace showing \[^18^F\]**2** in the crude reaction mixture. **Bottom**: microPET imaging (**A**, the white arrow indicates the tumor location) and *Ex vivo* PET/fluorescence imaging (**B**) of major organs and tumor 0.5 h after injection of \[^18^F\]**2**-RGD into a U87MG tumor bearing nude mouse. The fluorescence images were obtained by irradiation of the organs at λ= 535 nm. The fluorescence image was reconstructed based on the emission intensity measured at λ= 580 nm. 1: Heart, 2: Liver, 3: Kidneys, 4:Muscle, 5: Tumor.
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###### 

Radiosynthetic results for the ^18^F-labeling of **1**^+^OTf^-^.
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^a^% RCY calculated from the radio HPLC analysis by dividing the area of the product peak by the sum of all the peak areas. The RCYs were decay-corrected. The final reaction volume was kept at 70 µL for entry 3-15.
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